The healthcare industry is setting new trends every day. One trend that has grabbed the attention of most of the people is copied bio-similar drugs. The U.S. government has faced a lot of issues, with respect to these drugs, but against all the odds, it has finally given them the long-awaited green light. According to reports, regulators in the U.S. have approved Zarxio; the first copied biosimilar drug of the country.

What’s Special About Zarxio:

The newly approved Zarxio has most of the ingredients similar to Neupogen or filgrastim, which marked sales of $1.2 billion in 2014 across the globe. Both these drugs are developed and distributed by Amgen, which is a prominent American multinational biopharmaceutical company. The drug helps the patients in preventing any infection. It is mostly given to those who suffer from cancer.

Zarxio attracted quite a few controversies from the day of its launch, but FDA backed the drug always. It always believed that Zarxio could uplift the standards of healthcare treatments in the near future. Europe had approved biosimilar drugs in 2006, but patients in United States always struggled to get them. Earlier FDA didn’t have authority to approve any such drug, but Obama government passed a resolution named Obamacare in 2010, which made it possible for FDA to approve biosimilar drugs.

Unlike all the chemical drugs, bio-similar drugs are developed inside the living cells, which make it difficult for the companies to produce two identical drugs. According to experts, scientists can produce two similar bio-similar drugs, but not two identical ones.

Margaret Hamburg, Commissioner, FDA stated that after the approval of biosimilar drugs, it would become easier for the patients to get access to them as and then they want. It will not only improve the standards of the healthcare industry, but also make it easy for the patients to get proper treatment of life-threatening diseases.